Venetoclax and Decitabine in R/R T-ALL

Exclusion Criteria

• •Individuals in complete remission with previous treatment, if relapse or resistance is not confirmed by bone marrow examination or imaging/tissue examination.
• •Individuals who previously received venetoclax + decitabine treatment for T-lymphoblastic leukemia/lymphoma (participants who received venetoclax + decitabine treatment for a different type of cancer \[e.g., acute myeloid leukemia\] and have elapsed more than 1 year since the last treatment are allowed).
• •Pregnant or breastfeeding individuals.
• •Individuals who received systemic anticancer chemotherapy or participated in a clinical trial treatment within the past 2 weeks.
• •Individuals with active leukemia involving the central nervous system.
• •Individuals with a cancer type other than T-lymphoblastic leukemia/lymphoma that requires current active treatment (participants with a cancer type that has already been cured or is in a slow-progressing state without treatment, as determined by surgery/radiation/chemotherapy, may participate under the consultation of the clinical trial investigator).
• •Individuals with active human immunodeficiency virus (HIV) infection, hepatitis B/hepatitis C infection (participants without evidence of viral particles through PCR testing may be enrolled with the consent of an infectious disease specialist or hepatologist).
• •Uncontrolled bleeding.
• •Uncontrolled infection (bacterial, fungal, viral).
• •Uncontrolled mental illness.
• •Individuals who do not understand the informed consent or have difficulty in adequate communication, making them inappropriate for participation in the clinical trial.
• •Cases where the investigator judges that patient evaluation may be hindered or participation in the clinical trial is not appropriate.
• •Individuals who have a negative attitude towards participating in the clinical trial or who are unwilling to comply with the treatment and specimen collection schedule specified in the study protocol.